Dr. Lai-Goldman is the Chief Executive Officer and co-founder of GeneCentric Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing assays that enable oncologists and their patients to make informed, individualized, treatment decisions. She is also the managing partner of Personalized Science, LLC, a consulting company that is focused on innovative diagnostics for patients’ unmet clinical needs. Dr. Lai-Goldman currently serves on the board of directors of West Pharmaceutical Services, Inc., a provider of drug administration systems, and Qvella Corporation, a privately-held molecular diagnostics company. She is also a venture partner with Hatteras Venture Partners, a position she has held since August 2011. From 1990 to December 2008, Dr. Lai-Goldman served in various roles at Laboratory Corporation of America Holdings and its predecessor company, Roche Biomedical Laboratories, including Executive Vice President, Chief Medical Officer, and Chief Scientific Officer. Dr. Lai-Goldman received her medical degree from Columbia University College of Physicians and Surgeons.
Clinical Dx Showcase: GeneCentric Therapeutics
GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes.
Delivering Greater Precision to Precision Medicine
Our approach applies our Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we are defining responder populations based on subtypes throughout the drug development cycle.